azole antifungal drugs; therapeutic drug monitoring,; UHPLC-DAD; human serum; clinical practice
Abstract :
[en] Azole antifungals are a group of fungistatic agents that can be administered orally or parenterally. The
determination of the concentrations of these antifungals (miconazole, fluconazole, ketoconazole,
posaconazole, voriconazole, itraconazole, and its major active metabolite, hydroxy-itraconazole) in serum
can be useful to adapt the doses to pharmacological ranges because of large variability in the absorption
and metabolism of the drugs, multiple drug interactions, but also potential resistance or toxicity. A method
was developed and validated for the simultaneous determination of these drugs in serum utilizing ultra-high
pressure liquid chromatography and diode array detection (UHPLC-DAD). After a simple and rapid liquid–
liquid extraction, the pre-treated sample was analysed on an UHPLC-DAD system (Waters CorporationH).
The chromatographic separation was carried out on an Acquity BEH C18 column (Waters Corporation) with
a gradient mode of mobile phase composed of acetonitrile and aqueous ammonium bicarbonate 10.0 M
pH10. The flow rate was 0.4 ml/min and the injection volume was 5 ml. The identification wavelength varied
according to the drug from 210 to 260 nm. The method was validated by the total error method approach
by using an analytical validation software (eNnoval V3.0 ArlendaH). The seven azole antifungals were
identified by retention time and specific UV spectra, over a 13-minute run time. All calibration curves
showed good linearity (r2.0.99) in ranges considered clinically adequate. The assay was linear from 0.05
to 10 mg/l for voriconazole, posaconazole, itraconazole, hydroxy-itraconazole, and ketoconazole, from 0.3
to 10 mg/l for fluconazole, and from 0.1 to 10 mg/l for miconazole. The bias and imprecision values for intraand
inter-assays were lower than 10% and than 15%, respectively. In conclusion, a simple, sensitive, and
selective UHPLC-DAD method was developed and validated to determine seven azole antifungal drugs in
human serum. This method is applicable to patient samples, and can be applied successfully to clinical
applications and therapeutic drug monitoring.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
MISTRETTA, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Toxicologie clinique
DUBOIS, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Toxicologie clinique
DENOOZ, Raphael ; Centre Hospitalier Universitaire de Liège - CHU > Toxicologie clinique
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Language :
English
Title :
Simultaneous determination of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection
Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125:25-38.
Hochart S, Barrier F, Durand-Joly I, Horrent S, Decaudin B, Odou P. Les antifongiques systémiques. Partie 2: éléments thérapeutiques. Pharm Hosp. 2008;43:155-68.
Thiebaut A. Prophylaxie des infections fongiques invasives: nouvelles études cliniques. Hématologie. 2008;14:12-9.
Aguerre C, Azzoug M, Adehossi A, Pelloquin N. Les nouveaux antifongiques. Monit Hosp. 2011;240:21-31.
Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
Blanchet B. Suivi thérapeutique des médicaments antifongiques. Rev Fr Lab. 2004;365:39-47.
Lass-Flörl C. Triazole antifungal agents in invasive fungal infections. Drugs. 2011;71:2405-19.
Hussaini T, Rüping MJ, Farowski F, Vehreschild JJ, Cornely OA. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy. 2011;31:214-25.
Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother. 1997;40:753-64.
Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21: 580-6.
Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-72.
Verweij-van Wissen CP, Burger DM, Verweij PE, Aarnoutse RE, Brüggemann RJ. Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 2012;887-888:79-84.
Beste KY, Burkhardt O, Kaever V. Rapid HPLC-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clin Chim Acta. 2012;413:240-5.
Gordien JB, Pigneux A, Vigouroux S, Tabrizi R, Accoceberry I, Bernadou JM, et al. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal. 2009;50:932-8.
Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B. 2010;878:39-44.
Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, et al. Multiplex ultra-performance liquid chromatography- tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole- N-oxide, anidulafungin and caspofungin. Antimicrob Agents Chemother. 2010;54:5303-15.
Ng TK, Chan RC, Adeyemi-Doro FA, Cheung SW, Cheng AF. Rapid high performance liquid chromatographic assay for antifungal agents in human sera. J Antimicrob Chemother. 1996;37:465-72.
Hubert P, Nguyen-Huu, JJ, Boulanger B, Chapuzet E, Chiap P, Cohen N, et al. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - part I. J Pharm Biomed Anal. 2004;36:579-86.
Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Chiap P, Cohen N, et al. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal - part II. J Pharm Biomed Anal. 2007;45:70-81.
Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Cohen N, Compagnon PA, et al. Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal - part III. J Pharm Biomed Anal. 2007;45:82-96.
International Organization for Standardization. General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025. Geneva: International Organization for Standardization; 2005.
International Organization for Standardization. Medical laboratories - particular requirements for quality and competence. ISO 15189. Geneva: International Organization for Standardization; 2012.
Hulin A, Deguillaume AM, Bretagne S, Bézie Y. Bon usage des antifongiques dans le traitement des candidoses et aspergilloses invasives. J Pharm Clin. 2005;24:125-38.
Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Die Pharm. 2003;58:447-74.
Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S, et al. Analysis of recent pharmaceutical regulatory documents on analytical method validation. J Chromatogr A. 2007;1158:111-25.
Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24:1962-73.
Kobylińska M, Kobylińska K, Sobik B. High-performance liquid chromatographic analysis for the determination of miconazole in human plasma using solid-phase extraction. J Chromatogr B. 1996;685:191-5.
Sanford JP, Gilbert DN, Chambers HF, Eliopoulos GM, Moellering RC, Saag MS. The Sanford guide to antimicrobial therapy 2010-2011. Belgian/Luxembourg edition. Bruxelles: SBIMC-BVIKM; 2010. p. 213.